OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time - Trial NCT06216821
Access comprehensive clinical trial information for NCT06216821 through Pure Global AI's free database. This phase not specified trial is sponsored by Shenyang Northern Hospital and is currently Not yet recruiting. The study focuses on Acute Coronary Syndrome. Target enrollment is 3490 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shenyang Northern Hospital
Timeline & Enrollment
N/A
Feb 01, 2024
Dec 31, 2025
Primary Outcome
Net adverse clinical events (NACE)
Summary
Monotherapy with a P2Y12 inhibitor after a minimum period of DAPT following percutaneous
 coronary intervention (PCI) is an emerging de-escalation antiplatelet strategy in recent
 years. However, the optimal timing for de-escalating DAPT in ACS patients undergoing PCI
 remains debated. The OPT-CAD score is a risk stratification tool derived from Chinese
 patients which has been demonstrated superior predictive capabilities for ischemic events and
 all-cause mortality than the GRACE score. Therefore, we hypothesize that the OPT-CAD score
 can be used to guide the timing of the DAPT de-escalation strategy to monotherapy with P2Y12
 inhibitors for ACS patients, that is, low-risk patients could be de-escalated after 1 month,
 while high-risk patients could be de-escalated after 3 months, so as to achieve
 individualized antithrombotic therapy and maximize patient benefit.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06216821
Non-Device Trial